{
  "_metadata": {
    "version": "2.1",
    "ticker": "ARGX",
    "asset_name": "Efgartigimod",
    "extraction_date": "2026-02-11",
    "source_id": "argx_corporate_2026"
  },
  "asset": {
    "name": "Efgartigimod (VYVGART / VYVGART Hytrulo)",
    "company": "argenx SE",
    "ticker": "ARGX",
    "stage": "Approved (gMG, CIDP) / Phase 3 (Ocular MG, Myositis, ITP, Sjogren's) / Registrational (Seronegative gMG, Graves')",
    "modality": "Fc fragment (antibody fragment)",
    "ownership": "Wholly-owned",
    "one_liner": "Efgartigimod is the first-in-class FcRn-blocking Fc fragment approved for gMG and CIDP, with $4.2B in 2025 net sales and 6 upcoming Phase 3 readouts across autoimmune indications."
  },
  "target": {
    "name": "FcRn",
    "full_name": "Neonatal Fc Receptor",
    "class": "Receptor",
    "pathway": "IgG recycling / FcRn-mediated IgG homeostasis",
    "biology": {
      "simple_explanation": "FcRn is a receptor that rescues IgG antibodies from degradation, keeping their levels high in the blood. By blocking FcRn, efgartigimod accelerates breakdown of pathogenic IgG autoantibodies, reducing the autoimmune attack on the body's tissues.",
      "pathway_detail": null,
      "downstream_effects": [
        "Reduction of pathogenic IgG autoantibodies",
        "Reduction of total IgG levels"
      ]
    },
    "why_good_target": {
      "clinical_validation": "VYVGART approved in gMG (AChR+) and CIDP; ~19K patients treated globally; #1 prescribed biologic in MG driving 60% growth in overall MG biologics share",
      "genetic_validation": {
        "gain_of_function": null,
        "loss_of_function": null
      },
      "source": {
        "id": "argx_corporate_2026",
        "slide": 11,
        "verified": false
      }
    }
  },
  "mechanism": {
    "type": "FcRn blocker (Fc fragment)",
    "how_it_works": "Efgartigimod is an engineered Fc fragment that binds FcRn with high affinity, blocking its ability to recycle IgG antibodies, accelerating IgG degradation including pathogenic autoantibodies.",
    "differentiation": "First-in-class Fc fragment; first and only FcRn blocker approved in MG; available as IV (VYVGART) and SC with hyaluronidase (VYVGART Hytrulo PFS); autoinjector estimated 2027",
    "source": {
      "id": "argx_corporate_2026",
      "slide": 20,
      "verified": false
    }
  },
  "regulatory": {
    "designations": [
      {
        "type": null,
        "indication": "gMG (AChR+)",
        "date_granted": null,
        "source": {
          "id": "argx_corporate_2026",
          "slide": 23,
          "verified": false
        }
      }
    ],
    "planned_pathway": {
      "type": null,
      "surrogate_endpoint": null,
      "source": {
        "id": "argx_corporate_2026",
        "slide": null,
        "verified": false
      }
    }
  },
  "partnership": {
    "_note": "No co-development partner. Delivery technology partnerships only.",
    "partner": null,
    "territory": null,
    "economics": null,
    "delivery_partnerships": [
      {
        "partner": "Halozyme",
        "technology": "Hyaluronidase for SC formulation (PFS approved)",
        "source": {
          "id": "argx_corporate_2026",
          "slide": 16,
          "verified": false
        }
      },
      {
        "partner": "Ypsomed",
        "technology": "Autoinjector (estimated 2027)",
        "source": {
          "id": "argx_corporate_2026",
          "slide": 16,
          "verified": false
        }
      }
    ]
  },
  "pharmacology": {
    "pk_parameters": {
      "half_life": {
        "value": null,
        "population": null,
        "source": {
          "id": "argx_corporate_2026",
          "slide": null,
          "verified": false
        }
      },
      "cmax": {
        "value": null,
        "source": {
          "id": "argx_corporate_2026",
          "slide": null,
          "verified": false
        }
      },
      "auc": {
        "value": null,
        "source": {
          "id": "argx_corporate_2026",
          "slide": null,
          "verified": false
        }
      },
      "tmax": {
        "value": null,
        "source": {
          "id": "argx_corporate_2026",
          "slide": null,
          "verified": false
        }
      },
      "bioavailability": {
        "value": null,
        "source": {
          "id": "argx_corporate_2026",
          "slide": null,
          "verified": false
        }
      },
      "volume_of_distribution": {
        "value": null,
        "source": {
          "id": "argx_corporate_2026",
          "slide": null,
          "verified": false
        }
      }
    },
    "dose_response": {
      "doses_tested": null,
      "dose_rationale": null,
      "exposure_response": null,
      "recommended_dose": {
        "dose": null,
        "rationale": null,
        "source": {
          "id": "argx_corporate_2026",
          "slide": null,
          "verified": false
        }
      },
      "by_dose": null
    },
    "target_engagement": {
      "metric": "IgG reduction from baseline (%)",
      "by_dose": [
        {
          "dose": null,
          "engagement": "IgG reduction curve shown (slide 21) \u2014 efgartigimod achieves cyclical ~60-70% IgG reduction from baseline oscillating over 140-day period; no numeric axis values provided",
          "compartment": "blood",
          "source": {
            "id": "argx_corporate_2026",
            "slide": 21,
            "verified": false
          }
        }
      ]
    },
    "pk_summary": "PK/PD curve on slide 21 shows efgartigimod has cyclical IgG reduction pattern (oscillating between ~-20% and ~-70% from baseline) compared with ARGX-213 which achieves sustained ~-75-80% reduction. No numeric PK values provided."
  },
  "indications": {
    "lead": {
      "name": "Generalized Myasthenia Gravis (gMG)",
      "patient_population": "AChR+ gMG (approved); AChR- gMG including MuSK+, LRP4+, triple seronegative (pending approval by end of 2026)",
      "current_penetration": "17K addressable at launch; growing to 60K total addressable in US by 2030",
      "rationale": "Pathogenic IgG autoantibodies against AChR are central to disease; FcRn blockade directly reduces these autoantibodies",
      "source": {
        "id": "argx_corporate_2026",
        "slide": 12,
        "verified": false
      }
    },
    "expansion": [
      {
        "name": "CIDP",
        "stage": "Approved",
        "rationale": "IgG autoantibody-mediated; blockbuster status as of 3Q 2025; 12K addressable at launch, 42K total diagnosed",
        "source": {
          "id": "argx_corporate_2026",
          "slide": 13,
          "verified": false
        }
      },
      {
        "name": "Ocular MG",
        "stage": "Phase 3 (ADAPT Oculus)",
        "rationale": "First and only development in Ocular MG; adds ~7K patients to US addressable market",
        "source": {
          "id": "argx_corporate_2026",
          "slide": 12,
          "verified": false
        }
      },
      {
        "name": "Seronegative gMG",
        "stage": "Registrational (approval pending by end of 2026)",
        "rationale": "Adds ~11K patients; limited current treatment options",
        "source": {
          "id": "argx_corporate_2026",
          "slide": 12,
          "verified": false
        }
      },
      {
        "name": "Autoimmune Myositis (IIM)",
        "stage": "Phase 3 (ALKIVIA)",
        "rationale": "Phase 2 showed significant improvement in muscle strength (TIS); US prevalence 70K; no targeted therapies approved",
        "source": {
          "id": "argx_corporate_2026",
          "slide": 14,
          "verified": false
        }
      },
      {
        "name": "ITP",
        "stage": "Phase 3 (ADVANCE NEXT)",
        "rationale": "IgG autoantibodies against platelets; ADVANCE Phase 3 IV and Japan real world data support development",
        "source": {
          "id": "argx_corporate_2026",
          "slide": 24,
          "verified": false
        }
      },
      {
        "name": "Sjogren's Disease",
        "stage": "Phase 3 (UNITY)",
        "rationale": "Phase 2 reductions in systemic disease activity; Anti-Ro/SSA and Anti-La/SSB hallmarks; US prevalence 330K, 100K moderate-to-severe; no targeted therapies approved",
        "source": {
          "id": "argx_corporate_2026",
          "slide": 14,
          "verified": false
        }
      },
      {
        "name": "Graves' Disease",
        "stage": "Registrational",
        "rationale": null,
        "source": {
          "id": "argx_corporate_2026",
          "slide": 23,
          "verified": false
        }
      }
    ]
  },
  "clinical_data": {
    "trials": [
      {
        "name": "ADAPT Oculus",
        "nct_id": null,
        "phase": "Phase 3",
        "status": "Readout expected 1Q 2026",
        "design": null,
        "enrollment": null,
        "arms": null,
        "primary_endpoint": {
          "name": "MGII (novel primary endpoint)",
          "definition": null,
          "result": null,
          "source": {
            "id": "argx_corporate_2026",
            "slide": 26,
            "verified": false
          }
        },
        "secondary_endpoints": null,
        "biomarkers": null,
        "safety": null,
        "prior_evidence": "ADAPT ocular domain data and real-world case reports",
        "source": {
          "id": "argx_corporate_2026",
          "slide": 26,
          "verified": false
        }
      },
      {
        "name": "ALKIVIA",
        "nct_id": null,
        "phase": "Phase 3",
        "status": "Readout expected 3Q 2026",
        "design": null,
        "enrollment": null,
        "arms": null,
        "primary_endpoint": {
          "name": "TIS (Total Improvement Score) composite",
          "definition": null,
          "result": null,
          "source": {
            "id": "argx_corporate_2026",
            "slide": 26,
            "verified": false
          }
        },
        "secondary_endpoints": null,
        "biomarkers": null,
        "safety": null,
        "prior_evidence": "ALKIVIA PoC: significant improvement in muscle strength (TIS) in Phase 2",
        "source": {
          "id": "argx_corporate_2026",
          "slide": 26,
          "verified": false
        }
      },
      {
        "name": "ADVANCE NEXT",
        "nct_id": null,
        "phase": "Phase 3",
        "status": "Readout expected 4Q 2026",
        "design": null,
        "enrollment": null,
        "arms": null,
        "primary_endpoint": {
          "name": "Cumulative platelet count",
          "definition": null,
          "result": null,
          "source": {
            "id": "argx_corporate_2026",
            "slide": 26,
            "verified": false
          }
        },
        "secondary_endpoints": null,
        "biomarkers": null,
        "safety": null,
        "prior_evidence": "ADVANCE Phase 3 IV and real world data from Japan",
        "source": {
          "id": "argx_corporate_2026",
          "slide": 26,
          "verified": false
        }
      },
      {
        "name": "UNITY",
        "nct_id": null,
        "phase": "Phase 3",
        "status": "Readout expected 2H 2027",
        "design": null,
        "enrollment": null,
        "arms": null,
        "primary_endpoint": {
          "name": "Not specified (described as 'challenging primary endpoint')",
          "definition": null,
          "result": null,
          "source": {
            "id": "argx_corporate_2026",
            "slide": 26,
            "verified": false
          }
        },
        "secondary_endpoints": null,
        "biomarkers": null,
        "safety": null,
        "prior_evidence": "RHO and DAHLIAS PoC: reductions in systemic disease activity in Phase 2",
        "source": {
          "id": "argx_corporate_2026",
          "slide": 26,
          "verified": false
        }
      }
    ]
  },
  "differentiation_claims": [
    {
      "claim": "#1 prescribed biologic in MG, driving 60% growth in overall MG biologics share",
      "evidence_level": "management_claim",
      "caveat": "Based on argenx market research as of 4Q 2025",
      "source": {
        "id": "argx_corporate_2026",
        "slide": 11,
        "verified": false
      }
    },
    {
      "claim": "First-in-class Fc fragment with 15+ indications",
      "evidence_level": "management_claim",
      "caveat": null,
      "source": {
        "id": "argx_corporate_2026",
        "slide": 20,
        "verified": false
      }
    },
    {
      "claim": "First and only development program in Ocular MG",
      "evidence_level": "management_claim",
      "caveat": null,
      "source": {
        "id": "argx_corporate_2026",
        "slide": 12,
        "verified": false
      }
    },
    {
      "claim": "70% of new MG patients coming directly from orals (earlier line adoption)",
      "evidence_level": "management_claim",
      "caveat": "argenx market research",
      "source": {
        "id": "argx_corporate_2026",
        "slide": 11,
        "verified": false
      }
    }
  ],
  "competitive_landscape": {
    "competitors": null,
    "_note": "No specific competitor drugs named in this presentation"
  },
  "ip_landscape": {
    "composition_of_matter": {
      "patent_expiry": null,
      "source": {
        "id": "argx_corporate_2026",
        "slide": null,
        "verified": false
      }
    },
    "method_of_use": {
      "patent_expiry": null,
      "source": {
        "id": "argx_corporate_2026",
        "slide": null,
        "verified": false
      }
    },
    "regulatory_exclusivity": {
      "type": null,
      "expiry": null
    },
    "freedom_to_operate": null
  },
  "market_opportunity": {
    "tam": null,
    "patient_population": "MG: 17K at launch -> 60K US TAM by 2030; CIDP: 12K at launch, 42K total diagnosed; Myositis: 70K US; Sjogren's: 330K US (100K moderate-to-severe); ~19K patients on VYVGART globally",
    "unmet_need": "No targeted therapies approved for Myositis or Sjogren's; limited options in seronegative and ocular MG",
    "pricing_benchmark": null,
    "peak_sales_estimate": null,
    "source": {
      "id": "argx_corporate_2026",
      "slide": 12,
      "verified": false
    }
  },
  "catalysts": [
    {
      "event": "Ocular MG Phase 3 readout (ADAPT Oculus)",
      "timing": "1Q 2026",
      "importance": "critical",
      "what_to_watch": "MGII novel primary endpoint; first and only development in Ocular MG",
      "bull_scenario": "Positive data adds ~7K patients to US addressable market",
      "bear_scenario": "Novel endpoint may not capture clinically meaningful benefit"
    },
    {
      "event": "AChR- gMG (seronegative) approval decision",
      "timing": "By end of 2026",
      "importance": "critical",
      "what_to_watch": "Broadest MG label (MuSK+, LRP4+, triple seronegative)",
      "bull_scenario": "Adds ~11K seronegative patients to US addressable market",
      "bear_scenario": "Regulatory delays or additional data requirements"
    },
    {
      "event": "Myositis Phase 3 readout (ALKIVIA)",
      "timing": "3Q 2026",
      "importance": "critical",
      "what_to_watch": "TIS composite endpoint; 70K US prevalence",
      "bull_scenario": "Opens rheumatology market with no targeted therapies",
      "bear_scenario": "Disease heterogeneity may lead to mixed results"
    },
    {
      "event": "ITP Phase 3 readout (ADVANCE NEXT)",
      "timing": "4Q 2026",
      "importance": "critical",
      "what_to_watch": "Cumulative platelet count in difficult-to-treat patients",
      "bull_scenario": "Validates broad ITP utility",
      "bear_scenario": "Difficult-to-treat population may limit effect size"
    },
    {
      "event": "Sjogren's Phase 3 readout (UNITY)",
      "timing": "2H 2027",
      "importance": "high",
      "what_to_watch": "Challenging primary endpoint; 330K US prevalence",
      "bull_scenario": "Opens largest indication by patient population",
      "bear_scenario": "Historically difficult endpoint in Sjogren's trials"
    }
  ],
  "investment_analysis": {
    "probability_of_success": null,
    "key_risks": [
      "Novel/composite primary endpoints across multiple Phase 3 trials",
      "ITP trial in difficult-to-treat patients may limit generalizability",
      "FcRn class competition",
      "Rheumatology commercial expansion requires new prescriber base"
    ],
    "bull_case": [
      "Market-leading franchise with $4.2B revenue and 90% YoY growth",
      "Label expansion to 60K US addressable MG patients by 2030",
      "CIDP blockbuster validates multi-indication strategy"
    ],
    "bear_case": [
      "Novel Phase 3 endpoints create binary risk across 4 readouts in 2026",
      "Rheumatology expansion requires new commercial infrastructure"
    ],
    "key_debates": [
      {
        "question": "Will the MGII novel primary endpoint succeed in Ocular MG?",
        "bull_view": "ADAPT ocular domain data and real-world case reports support endpoint",
        "bear_view": "Novel endpoints carry inherent risk",
        "what_resolves_it": "1Q 2026 Phase 3 readout"
      }
    ]
  },
  "_extraction_quality": {
    "completeness_score": "medium",
    "missing_critical_fields": [
      "PK parameters",
      "Dosing regimen",
      "Safety data",
      "Trial enrollment/arms",
      "NCT IDs",
      "Competitive landscape",
      "IP/patents",
      "Regulatory designations"
    ],
    "recommended_supplementary_sources": [
      "argenx 20-F for financials and IP",
      "ClinicalTrials.gov for trial details",
      "VYVGART prescribing information",
      "ADAPT/ADAPT+ published papers"
    ]
  }
}